Lipocine Inc.
LPCN
Positions held
Your positionsLPCN isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $15.91M | Enterprise value | -$7.10M | Trailing P/E | — | Forward P/E | -1.56 |
| PEG | — | Price / book | 0.73 | Beta | 0.40 | Dividend yield | 0.00% |
| Revenue growth | -69.5% | Earnings growth | — | Gross margin | 100.0% | Operating margin | -15.0% |
| Profit margin | 0.0% | ROE | -60.9% | ROA | -37.0% | Debt / equity | 0.01 |
| Current ratio | 11.48 | Free cash flow | -$6.94M | Analyst recommendation | none | Mean target | $5.00 |
| 52w high | $12.37 | 52w low | $1.81 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.2M | $0.1M | $1.1M | $0.1M | $0.6M | — |
| Op margin | -1495.1% | -3224.1% | -219.6% | -2933.5% | -386.0% | — |
| Net income | -$2.6M | -$3.7M | -$2.4M | -$3.2M | -$2.2M | — |
| Gross margin | -973.9% | — | — | — | -243.1% | — |
| Gross profit | -$1.9M | — | — | — | -$1.5M | — |
| Operating income | -$2.8M | -$3.8M | -$2.5M | -$3.4M | -$2.4M | — |
- Revenue +59% vs prior quarter ($0.2M vs $0.1M).
- Gross margin -973.9% (was -243.1% prior quarter).
- Operating margin expanded to -1495.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $2.0M | $11.2M | -$2.9M | $0.5M | — |
| Op margin | -524.7% | -10.3% | 629.0% | -2423.9% | — |
| Net income | -$9.6M | $0.0M | -$16.4M | -$10.8M | — |
| Gross margin | -334.3% | 34.3% | 456.9% | -1611.4% | — |
| Gross profit | -$6.6M | $3.8M | -$13.0M | -$8.1M | — |
| Operating income | -$10.4M | -$1.2M | -$17.9M | -$12.1M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Here's Why You Should Add LPCN Stock to Your Portfolio Now
2026-10-07 · Top Midday Gainers
2026-10-07 · BC-Most Active Stocks
2026-10-07 · Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market
2026-10-07 · Lipocine stock surges 30% on Health Canada drug approval
2026-10-07 · LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today
2026-10-07 · Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
2026-10-07 · Top Premarket Gainers
2026-09-23 · Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
2026-09-14 · Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
2026-09-10 · Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-08-04 · Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026
Price (daily)
Full chart · RSI · MACD · patterns